AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04758806 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbial transplantation
Description: Procured faeces procured from unrelated donor
Study NCT04477369 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1439
Description: 300mg single dose
Study NCT04477369 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DWJ1464
Description: 300mg single dose
Study NCT04477369 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DWC202003
Description: 300mg single dose
Study NCT04477369 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: DWC202004
Description: 300mg single dose
Study NCT00993551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary surgery for cleft palate
Description: Surgery completed using the Sommerlad technique
Study NCT00761228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine
Description: Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
Study NCT00761228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive a continues subcutaneous infusion of saline solution.
Study NCT03432481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicompartmental Knee Arthroplasty Surgery
Description: Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
Study NCT03432481 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodycad Unicompartmental Knee System (BUKS)
Description: Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
Study NCT02566057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGx testing guided treatment (PGT)
Description: Genecept Assay (GeneceptTM Assay) will provide information on genotypes of genetic variants that are relevant to psychiatric drug response. The provider can use the information to decide on which psychotropic drugs to use.
Study NCT00352326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reprogramming assisted communication device interface
Description: The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
Study NCT02961439 — intervention group
Intervention type: BEHAVIORAL
Intervention: Epworth Richmond's Echocardiography Focused Year
Description: a year long echo teaching program
Study NCT04263168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous Glucose monitoring in the perioperative period
Description: All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
Study NCT04263168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Continuous Glucose monitoring in the perioperative period
Description: All participants will undergo medical and metabolic profiling before surgery at baseline, and during the first two weeks following surgery. Metabolic profiling will take place during a run-in session in the Sheba medical center, that will include (A) A detailed briefing on study design, goals, samples collection and OGTT, as well as home sample-collecting kit distribution (B) Installation of a continuous glucose monitoring system (CGM, Abbott 'freeStyle Libre').
Study NCT04447105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: total intravenous anesthesia with propofol
Description: In the TIVA group, general anesthesia is induced and maintained with a target-controlled infusion of propofol using infusion pump (Orchestra®; Fresenius Vial, Brezins, France). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
Study NCT04447105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhalation anesthesia with desflurane
Description: In the desflurane group, anesthesia is induced with propofol 1-2 mg/kg and maintained with desflurane (5-7 vol %). In both groups, remifentanil is continuously infused throughout the surgery for balanced anesthesia, adjusted to maintain arterial pressure.
Study NCT00085553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study NCT00085553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00085553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00085553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study NCT01581177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 25 mcg/inh
Description: Albuterol DPI with 25 mcg Albuterol/inhalation
Study NCT01581177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 90 mcg/inh
Description: Albuterol DPI with 90 mcg Albuterol/inhalation
Study NCT01581177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Placebo DPI with 0 mcg Albuterol/inhalation
Study NCT01581177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: Placebo DPI with 0 mcg Albuterol/inhalation
Study NCT01581177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol MDI 90 mcg/inh
Description: Albuterol MDI with 90 mcg Albtuerol/inhalation
Study NCT02144792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C] -verapamil PET
Description: While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using \[11C\] -verapamil, a substrate of P-gp.
Study NCT00545753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad
Description: 10 minute topical application product, following by a complete rinse off.
Study NCT03292510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GO-OUT Group
Description: Following a baseline assessment, eligible participants will be stratified by site, and randomly assigned to receive the 1-day educational workshop and 3-month outdoor mobility program (GO-OUT intervention). Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline.
Study NCT03292510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Workshop Group
Description: the 1-day workshop plus reminders. Follow-up evaluations will occur at 3, 5.5 and 12 months from baseline
Study NCT00503893 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.
Study NCT00503893 — intervention group
Intervention type: OTHER
Intervention: Blood specimen
Description: Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
Study NCT04771845 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: Magnetic stimulation to alter neural activity
Study NCT00026091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenretinide
Description: Given orally
Study NCT00026091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00026091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04414852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: All the subjects will be administrated with 250mg apatinib on day 1
Study NCT04414852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate
Description: All the subjects will be administrated with 250mg apatinib on day 1
Study NCT01534273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721
Description: Administered orally.
Study NCT01534273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT03487770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Oral Solution
Description: Aripiprazole 2\~15 mg/day (2\~15 mL/day)
Study NCT03487770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Solution
Description: Placebo 2\~15 mg/day (2\~15 mL/day)
Study NCT02067520 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: intrathecal hydromorphone (IT hydromorphone)
Study NCT04294537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: At the end of surgery patients will receive bilateral ultrasound-guided single-shot TAP block: 0,15% levobupivacaine 0,75 mg/kg per side will be injected between internal oblique and transveralis fascia
Study NCT04294537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LIA local infiltration
Description: At the end of surgery 0,5% levobupivacaine 1.5 mg/kg, equally distributed between ports, injected in the skin and subcutaneous tissue during wound closure.
Study NCT00545753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinosad
Description: 10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
Study NCT00545753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 1%
Description: Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
Study NCT03442153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Solgar No7 Complex
Description: Solgar No7 Capsules
Study NCT03442153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets Cellulose
Study NCT04174703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-compassionate letter-writing intervention
Description: Participants in this condition will be asked to engage in an online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks.
Study NCT04294537 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv.
Study NCT04294537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia will be induced with fentanyl 1,5 mcg/kg, propofol 2 mg/kg, rocuronium 0,6 mg/kg; after intubation anesthesia will be mantained with sevoflurane (MAC 1).~30 minutes after induction will be administered paracetamol 15 mg/kg iv.
Study NCT04294537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postperative analgesia
Description: During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours.
Study NCT04294537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postperative analgesia
Description: During first 48 hours after surgery all patients wil receive paracetamol 15 mg/kg iv every 8 hours and ibuprofen 10 mg/kg orally (or through gastric tube) every 12 hours after surgery.~In case of severe pain tramadol 0,5 mg/kg will be administered iv every 8 hours.
Study NCT03242941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein ablation
Description: After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
Study NCT03547323 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 Dialyzer
Description: An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
Study NCT03547323 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FX80 Dialyzer
Description: An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
Study NCT02664142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BIS Group
Description: BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
Study NCT02664142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-BIS Group
Description: BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
Study NCT02664142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaesthetics
Description: Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
Study NCT01834547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drugs use: methylphenidate
Description: 40 mg tablets
Study NCT01834547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug use: modafinil
Description: 40 mg tablets
Study NCT01834547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine
Description: 400 mg
Study NCT01834547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01956890 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PET
Description: 18F-FLT PET and MRI of the breast
Study NCT03351543 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microbial inoculate
Description: volunteers will regularly receive microbial inoculate that they do not use orally
Study NCT00430846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-35
Description: Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
Study NCT00904007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Spaced Education (ISE) --- online education
Description: ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions.
Study NCT04521595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weigh Smart Telehealth intervention
Description: Trial of the group program (nutrition, exercise) delivered via telehealth through fruit street on the Eastern Shore and Western Maryland with use of noninvasive lifestyle tracking options (drink water aquarium app for water consumption and fitbit - steps, sleep monitoring) provides novel options for expansion of family- based lifestyle intervention to underserved areas. We plan as a pilot study to assess the sensitivity of noninvasive measures for the detection of sleep apnea (pediatric sleep questionnaire (PSQ) and fitbit sleep data) in comparison to clinically indicated polysomnography among children with clinical suspicion for sleep apnea.
Study NCT02886923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hioxifilcon A Test
Description: contact lens made with hioxifilcon A material
Study NCT02886923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hioxifilcon A Test
Description: contact lens made with hioxifilcon A material
Study NCT02886923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hioxifilcon A With Cosmetic Ring Control
Description: contact lens made with hioxifilcon A material with a cosmetic ring on the lens
Study NCT02886923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hioxifilcon A With Cosmetic Ring Control
Description: contact lens made with hioxifilcon A material with a cosmetic ring on the lens
Study NCT03151850 — intervention group
Intervention type: OTHER
Intervention: ulcerative colitis
Description: We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
Study NCT03151850 — intervention group
Intervention type: OTHER
Intervention: Control
Description: We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
Study NCT00509717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive implementation programme
Description: educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
Study NCT00509717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: educational manual
Study NCT01201642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
Study NCT01201642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
Study NCT01201642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: other treatment
Description: common medicine or other physical treatment which are different from those 5 Arms Previously.
Study NCT02361866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1107
Description: 0.5 ml, Intramuscular, single dose(day0)
Study NCT02361866 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus and Diphtheria(Td vaccine)
Description: 0.5ml, Intramuscular, single dose(day0) only applicable step1
Study NCT01663389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 1000 mg containing radioactive 14C-GSK1322322
Description: GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
Study NCT01663389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Description: GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
Study NCT02862301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT02862301 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Study NCT01219543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480 Daily
Description: Oral Dose, Capsule, Daily Dosing
Study NCT01219543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1480 BID
Description: Oral Dose, Capsule, BID Dosing
Study NCT02324751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-TCV
Description: Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge
Study NCT02324751 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi-PS Vaccine
Description: Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge
Study NCT02324751 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Control (Men ACWY)
Description: Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge